10-12 September 2018 //  Lancaster Royal Hotel, London


Toby Toward

Dr Toby Toward

Head of Commercial Strategy, Immunocore

Dr. Toby Toward is passionate about enabling great science to be developed into clinically and economically meaningful medicines, which offer value to patients, healthcare providers and payers.

Over his 20-year career in biotech, academia and large pharma, Toby has a demonstrated business success in leading teams to deliver clinical and economic development programmes that advance an asset’s value in becoming a meaningful medicine.

Most recently, Toby has worked as the Global Head of Pricing and Reimbursement at Pharmaxis, an Australian biotech. Previous to this, he held senior positions at GSK (Global Strategy Director – Respiratory R&D), The Medicines Company (Director – Global Competitive Strategy; Global HE&OR and Market Access), and various management roles within Programme Development, Clinical Research and Clinical Pharmacology.

During his career, Toby has successfully delivered more than 70 Health Technology Assessments (HTAs) and market access submissions to international pricing reimbursement authorities. Toby has also gained extensive experience in the strategic evaluation of assets for in-/out-licensing, as well as in the management of full drug development processes from target selection through to phase III/IV trials – each designed to efficiently demonstrate asset value to the regulator, healthcare systems payers, physicians and patients.

Toby has a PhD in Clinical Pharmacology from The Welsh School of Pharmacy, with additional degrees from Leeds University (Pharmacology, B.Sc.) and Aberdeen University (Health Economics).


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad